Moderna slides as flu-vaccine regulatory overhang and risk-off trading weigh on shares
Moderna shares fell about 3% Tuesday as investors continued to discount near-term revenue catalysts after recent flu-program headlines and a broader risk-off tape. The stock has also been pressured by lingering regulatory uncertainty around its seasonal flu shot mRNA-1010 after earlier FDA filing setbacks, keeping sentiment fragile.
1. What’s moving the stock
Moderna (MRNA) is down about 3% in Tuesday trading, extending a choppy stretch where the market has struggled to assign a clear near-term earnings catalyst to the company’s respiratory portfolio. Even with ongoing progress across flu and pandemic-influenza programs, the stock remains sensitive to sentiment shifts and incremental headlines that don’t immediately translate into 2026 revenue visibility. (investing.com)
2. The key overhang investors are focused on
A major pressure point has been the regulatory path for Moderna’s investigational seasonal influenza vaccine mRNA-1010. Earlier this year, the FDA issued a Refusal-to-File decision tied to trial design/comparator issues, and while Moderna has worked to address FDA concerns and other jurisdictions have been reviewing the program, the prior U.S. setback continues to weigh on confidence in timing and commercial ramp assumptions. (biospace.com)
3. Recent pipeline progress isn’t translating into immediate upside
Within the past week, Moderna disclosed the start of a Phase 3 study for its investigational H5 pandemic influenza vaccine candidate (mRNA-1018), supported by CEPI, with first participants dosed in the U.S. and U.K. While that development supports longer-term pandemic preparedness positioning, it does not immediately resolve the near-term question of how quickly Moderna can broaden durable, recurring respiratory-vaccine revenue beyond COVID-related demand. (stocktitan.net)
4. What to watch next
Traders will be watching for any additional clarity on the U.S. review timeline for mRNA-1010 and whether Moderna can de-risk its respiratory franchise with clearer regulatory milestones and commercialization details. Any updates on study designs requested by regulators, expected decision windows, or updated financial commentary could quickly shift the narrative—either stabilizing the shares or extending the selloff if timelines slip again. (medicaleconomics.com)